Dynavax to Report First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024

Rhea-AI Summary

Dynavax Technologies (DVAX) will report its first quarter 2024 financial results on May 8, 2024, after the U.S. financial markets close. The company will host a conference call and live audio webcast on the same day at 4:30 p.m. ET/1:30 p.m. PT. Participants can access the webcast through the 'Events & Presentations' page on the Company's website. A replay will be available for 30 days. To join the call, participants need to register using the caller registration link.

EMERYVILLE, Calif., April 24, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report first quarter 2024 financial results on Wednesday, May 8, 2024, after the U.S. financial markets close.

Dynavax will host a conference call and live audio webcast on Wednesday, May 8, 2024, at 4:30 p.m. ET/1:30 p.m. PT.

The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations. A replay of the webcast will be available for 30 days following the live event.

To dial into the call, participants will need to register for the call using the caller registration link. It is recommended that participants dial into the conference call or log into the webcast approximately 10 minutes prior to the call.

About Dynavax
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B^® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union and Great Britain for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018® adjuvant, currently used in multiple adjuvanted COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant as a premier vaccine adjuvant with adjuvanted vaccine clinical programs for shingles and Tdap, and through global collaborations, currently focused on adjuvanted vaccines for COVID-19, plague, seasonal influenza and universal influenza. For more information about our marketed products and development pipeline, visit www.dynavax.com and follow Dynavax on LinkedIn and Twitter.

For Investors/Media:
Paul Cox
pcox@dynavax.com
510-665-0499 

Nicole Arndt
narndt@dynavax.com
510-665-7264

View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-report-first-quarter-2024-financial-results-and-host-conference-call-on-may-8-2024-302126629.html

SOURCE Dynavax Technologies

FAQ

When will Dynavax Technologies (DVAX) report its first quarter 2024 financial results?

Dynavax Technologies (DVAX) will report its first quarter 2024 financial results on May 8, 2024, after the U.S. financial markets close.

What time will the conference call and live audio webcast be held on May 8, 2024?

The conference call and live audio webcast will be held on May 8, 2024, at 4:30 p.m. ET/1:30 p.m. PT.

How can participants access the live audio webcast?

Participants can access the live audio webcast through the 'Events & Presentations' page on the 'Investors' section of Dynavax Technologies 's website.

Is there a replay available for the webcast?

Yes, a replay of the webcast will be available for 30 days following the live event.

What do participants need to do to join the conference call?

Participants need to register for the call using the caller registration link.